Depression treatment
Antidepressant adverse events cohort
Open access · cc by · source: Europe PMC
In 238,963 adults aged 20–64 with depression, most used antidepressants and several common agents associated with higher fall rates versus non-use.
Study at a glance
- Design
- Cohort — UK primary-care database; newly diagnosed depression followed for adverse events
- N
- N=238963 · Final eligible cohort; 87.7% received antidepressants during follow-up
- Population
- Adults aged 20–64 with newly diagnosed depression in UK primary care
- Outcome
- Adverse outcomes (including falls) by antidepressant class/drug vs non-use
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
87.7% received antidepressants; citalopram, fluoxetine, and amitriptyline were most prescribed; 8 of 11 common drugs linked to significantly higher falls vs non-use over 5 years.
Methodology
UK primary-care database cohort followed eligible newly diagnosed depression patients for adverse outcomes across antidepressant classes and individual drugs.
Limitations
Observational signals can reflect confounding by indication; absolute risks and benefits still need joint clinical judgment.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Null and protective HRs are not interchangeable with 'safe' or 'preventive.' The anaesthetic trial's HR near 1 is limited by rare mortality and differing opioid co-analgesia; the alcohol paper's HR 0.72 cannot prove drinking prevents depression; the antidepressant-adverse-event cohort links several drugs to more falls versus non-use, which may still be confounding by indication.
Evidence for the claim as stated.
A UK primary-care cohort of newly diagnosed depression found 87.7% received antidepressants (citalopram, fluoxetine and amitriptyline most often), and 8 of 11 common drugs were linked to significantly higher falls versus non-use over 5 years. Observational signals can reflect confounding by indication; absolute risks still need to be weighed against benefit.
Evidence for the claim as stated.
Protective lifestyle HRs and harmful drug HRs are not interchangeable clinical instructions. Diet-quality HRs around 0.74–0.78 and HLI HRs of 0.67–0.77 do not prove that prescribing a diet would prevent depression or diabetes, while extra falls on named antidepressants may mark who is prescribed them rather than a pure drug effect. Norwegian cancer-survival SES gradients even became non-significant after stage and smoking were in the model.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Null and protective HRs are not interchangeable with 'safe' or 'preventive.' The anaesthetic trial's HR near 1 is limited by rare mortality and differing opioid co-analgesia; the alcohol paper's HR 0.72 cannot prove drinking prevents depression; the antidepressant-adverse-event cohort links several drugs to more falls versus non-use, which may still be confounding by indication.
- Supports · Propofol vs sevoflurane and breast cancer survival
- Supports · Wine, alcohol, and depression
Protective lifestyle HRs and harmful drug HRs are not interchangeable clinical instructions. Diet-quality HRs around 0.74–0.78 and HLI HRs of 0.67–0.77 do not prove that prescribing a diet would prevent depression or diabetes, while extra falls on named antidepressants may mark who is prescribed them rather than a pure drug effect. Norwegian cancer-survival SES gradients even became non-significant after stage and smoking were in the model.
- Supports · Diet quality and depression risk
- Supports · Healthy lifestyle and multimorbidity risk
- Supports · Does socioeconomic status change cancer survival?
Related papers in this topic
Same topic cluster — not a recommendation engine.